---
title: "Rhythm Pharma Q3 product revenue up 54% yr/yr on IMCIVREE sales"
description: "Rhythm Pharma Q3 product revenue up 54% yr/yr on IMCIVREE sales"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/264214976.md"
published_at: "2025-11-04T12:09:12.000Z"
---

# Rhythm Pharma Q3 product revenue up 54% yr/yr on IMCIVREE sales

)

Overview

-   Rhythm Q3 2025 product revenue rises 54% yr/yr, driven by IMCIVREE sales
-   Net income for Q3 2025 misses analyst expectations, larger loss reported
-   FDA accepts sNDA for setmelanotide in acquired hypothalamic obesity, decision by Dec 20

Outlook

-   Company expects FDA decision on sNDA by December 20, 2025
-   Rhythm anticipates Q4 2025 results from Phase 2 trial in Prader-Willi syndrome
-   Company updates 2025 Non-GAAP Operating Expenses guidance to $295 mln-$315 mln

Result Drivers

-   U.S. SALES GROWTH - Revenue from U.S. sales increased 19% sequentially, driven by growth in IMCIVREE sales for BBS
-   INTERNATIONAL SALES DECLINE - Revenue outside the U.S. decreased 21% sequentially due to ordering variability and a one-time pricing adjustment in France

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

### Q3 $51.29

Product mln

Revenue

Q3 Net Miss -$52.90 -$45.50

Income mln mln (11

Analysts

)

Q3 Basic -$0.82

### EPS

### Q3 -$52.65

Operatin mln

g Income

Analyst Coverage

-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 14 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”
-   The average consensus recommendation for the pharmaceuticals peer group is “buy”
-   Wall Street’s median 12-month price target for Rhythm Pharmaceuticals Inc is $121.50, about 6.4% above its November 3 closing price of $113.74

Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

### Related Stocks

- [RYTM.US - Rhythm Pharma](https://longbridge.com/en/quote/RYTM.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Rhythm Pharmaceuticals Eyes March 20 HO PDUFA, Highlights IMCIVREE Growth at Guggenheim Conf. | Rhythm Pharmaceuticals (NASDAQ:RYTM) CFO Hunter Smith discussed the company's upcoming PDUFA date of March 20 for hypoth | [Link](https://longbridge.com/en/news/275994191.md) |
| Assessing Rhythm Pharmaceuticals (RYTM) Valuation After Strong IMCIVREE Revenue Guidance For 2025 | Rhythm Pharmaceuticals (RYTM) has issued strong preliminary revenue guidance for its drug IMCIVREE, projecting approxima | [Link](https://longbridge.com/en/news/272952447.md) |
| FDA Accepts Biofrontera sNDA Filing for Ameluz PDT in Superficial Basal Cell Carcinoma | Biofrontera Inc. announced that the FDA has accepted its supplemental New Drug Application for Ameluz® in combination wi | [Link](https://longbridge.com/en/news/275619475.md) |
| Lenovo Group posts Q3 net income attributable $546 mln | Lenovo Group posts Q3 net income attributable $546 mln | [Link](https://longbridge.com/en/news/275704306.md) |
| Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks \| EBS Stock News | Emergent BioSolutions has received FDA approval for a supplemental New Drug Application for NARCAN® Nasal Spray multipac | [Link](https://longbridge.com/en/news/275820775.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
